Skip to main content

Table 4 Association of clinicopathological and genetic characteristics with disease- free survival in 51 FTC

From: Mutation profiles of follicular thyroid tumors by targeted sequencing

   Univariate Multivariate
Variations Cases HR(95% CI) P HR(95% CI) P
Sex    0.138   
 Male 16 1.000(reference)    
 Female 35 0.321 (0.072–1.439)    
Age at diagnosis, years    0.425   
 <55 29 1.000(reference)    
  ≥ 55 22 1.840 (0.411–8.234)    
Tumor size, cm    0.762   
  < 2.0 16 1.000(reference)    
 2.0~4.0 24 0.637 (0.128–3.158)    
  > 4.0 11 0.471 (0.049–4.531)    
Lymph node metastasis    0.005   0.442
 No 46 1.000(reference)   1.000(reference)  
 Yes 5 8.689 (1.929–39.145)   2.632 (0.224–30.951)  
AJCC Stage    0.017   0.770
 I + II 50 1.000(reference)   1.000(reference)  
 III + IV 1 15.827 (1.646–152.169)   1.742 (0.043–71.363)  
Histologic typea    0.039   0.182
 Minimally invasive /Encapsulated angioinvasive 39 1.000(reference)   1.000(reference)  
 Widely invasive 12 4.856 (1.084–21.761)   4.125 (0.515–33.049)  
Hürthle cell tumors    0.992   
 No 37 1.000(reference)    
 Yes 14 0.991 (0.192–5.111)    
EIF1AX mutation    0.007   0.366
 WT 48 1.000(reference)   1.000(reference)  
 Mut 3 9.989 (1.887–52.892)   3.998 (0.198–80.778)  
H/N/K-RAS mutation    0.393   
 WT 44 1.000(reference)    
 Mut 7 1.920 (0.430–8.586)    
TERTp mutation    0.024   0.162
 WT 40 1.000(reference)   1.000(reference)  
 Mut 11 5.633 (1.254–25.298)   3.841 (0.583–25.307)  
  1. abased on the 2017 World Health Organization classification of endocrine tumors; Abbreviations: WT wild-type, FTC follicular thyroid carcinoma, AJCC American Joint Committee on Cancer, 8th edition staging, HR hazard ratio, 95%CI 95% confidence interval, P P-value